Study on otherwise highly effective drugs being published in Journal of Hepatology
KINGSTON, R.I., December 13, 2016 — In the past few years, the normally reticent scientific community heralded as revolutionary new medications for Hepatitis C, saying the drugs would bring a major shift in the treatment of the chronic and potentially fatal viral infection that affects 150 million people worldwide.
They were right. These direct-acting drugs, which attack the processes that fueled the virus’s growth, resulted in cure rates well over 95 percent in a matter of weeks to a few months. They also gave new hope to the many people co-infected with HIV as well as Hepatitis C, who could now rid their bodies of the latter.